KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Free Cash Flow (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Free Cash Flow for 16 consecutive years, with -$19.5 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 0.84% to -$19.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$88.9 million through Dec 2025, up 14.97% year-over-year, with the annual reading at -$88.9 million for FY2025, 14.97% up from the prior year.
  • Free Cash Flow hit -$19.5 million in Q4 2025 for Inovio Pharmaceuticals, up from -$21.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$19.5 million in Q4 2025 to a low of -$78.7 million in Q2 2021.
  • Historically, Free Cash Flow has averaged -$37.5 million across 5 years, with a median of -$30.8 million in 2023.
  • Biggest five-year swings in Free Cash Flow: tumbled 189.35% in 2021 and later skyrocketed 57.32% in 2023.
  • Year by year, Free Cash Flow stood at -$38.1 million in 2021, then grew by 6.36% to -$35.6 million in 2022, then rose by 26.28% to -$26.3 million in 2023, then increased by 25.16% to -$19.7 million in 2024, then increased by 0.84% to -$19.5 million in 2025.
  • Business Quant data shows Free Cash Flow for INO at -$19.5 million in Q4 2025, -$21.7 million in Q3 2025, and -$20.9 million in Q2 2025.